EOLS - Evolus Announces Participation in November Investment Conferences
NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.
| Event: |
| Stifel 2021 Virtual Healthcare Conference |
| Date: |
| Tuesday, November 16, 2021 |
| Time: |
| 2:40 pm ET |
| Event: |
| Evercore ISI 4th Annual HealthCONx Virtual Conference |
| Date: |
| Tuesday, November 30, 2021 |
| Time: |
| 7:30 am ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com . Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau ® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com .
Jeuveau ® is a registered trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com